These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36344070)

  • 1. Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis.
    Guimbellot JS; Nichols DP; Brewington JJ
    Clin Chest Med; 2022 Dec; 43(4):617-630. PubMed ID: 36344070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.
    Arora K; Yang F; Brewington J; McPhail G; Cortez AR; Sundaram N; Ramananda Y; Ogden H; Helmrath M; Clancy JP; Naren AP
    Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1123-G1130. PubMed ID: 33949881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.
    Becq F
    Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.
    Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E
    J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine in cystic fibrosis: genistein supplementation as a treatment option for patients with a rare S1045Y-CFTR mutation.
    Arora K; Yarlagadda S; Zhang W; Moon C; Bouquet E; Srinivasan S; Li C; Stokes DC; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2016 Aug; 311(2):L364-74. PubMed ID: 27261451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new era of personalized medicine for cystic fibrosis - at last!
    Quon BS; Wilcox PG
    Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
    Derichs N
    Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from other fields of medicine, Part 2: Cystic fibrosis.
    Vijaykumar K; Rowe SM
    Handb Clin Neurol; 2023; 192():119-130. PubMed ID: 36796937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients.
    Amaral MD
    J Intern Med; 2015 Feb; 277(2):155-166. PubMed ID: 25266997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion.
    Shibata S; Ajiro M; Hagiwara M
    Cell Chem Biol; 2020 Dec; 27(12):1472-1482.e6. PubMed ID: 32905759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating the genetics of cystic fibrosis to personalized medicine.
    Corvol H; Thompson KE; Tabary O; le Rouzic P; Guillot L
    Transl Res; 2016 Feb; 168():40-49. PubMed ID: 25940043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on Clinical Outcomes of Highly Effective Modulator Therapy.
    Gifford AH; Taylor-Cousar JL; Davies JC; McNally P
    Clin Chest Med; 2022 Dec; 43(4):677-695. PubMed ID: 36344074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of CFTR modulators for the treatment of cystic fibrosis.
    Lopes-Pacheco M; Pedemonte N; Veit G
    Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
    Ensinck MM; Carlon MS
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.